Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES 简体中文 中文 हिन्दी HI
Sign Up
Log in
United Therapeutics Corp banner

United Therapeutics Corp
XMUN:UTH

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
XMUN:UTH
Watchlist
Price: 526.6 EUR
Market Cap: €14.9B
Write Note Create Alert
USD
Metric FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Cash & Cash Equivalents
1B 705.1m 669.2m 738.4m 738.7m 894.8m 961.2m 1.2B 1.7B 1.6B
Cash Equivalents
1B 705.1m 669.2m 738.4m 738.7m 894.8m 961.2m 1.2B 1.7B 1.6B
Short-Term Investments
27.8m 222.3m 746.7m 747.5m 1.1B 1B 1.9B 1.8B 1.6B 1.4B
Total Receivables
214.5m 297.1m 175.7m 151.4m 157.4m 198.7m 220.4m 278.9m 279.3m 350.2m
Accounts Receivables
214.5m 297.1m 175.7m 151.4m 157.4m 198.7m 220.4m 278.9m 279.3m 350.2m
Other Receivables
0 0 0 0 0 0 0 0 0 0
Inventory
100m 107.9m 101m 93.4m 86.5m 93.8m 102m 111.8m 157.9m 183.1m
Other Current Assets
59.5m 115.5m 75.4m 133.8m 88.3m 100.4m 219.2m 166.2m 169.7m 248.9m
Total Current Assets
1.4B 1.4B 1.8B 1.9B 2.2B 2.3B 3.4B 3.6B 3.9B 3.7B
PP&E Net
489.3m 545.7m 699.7m 743.3m 731.6m 780.9m 861.5m 1B 1.2B 1.7B
PP&E Gross
489.3m 545.7m 699.7m 743.3m 731.6m 780.9m 861.5m 1B 1.2B 1.7B
Accumulated Depreciation
(175m) (202.5m) (234.6m) (269.4m) (309.3m) (342.4m) (382.7m) (428.2m) (491.2m) (567.8m)
Intangible Assets
23.5m 31.9m 139.3m 130.3m 130.1m 16.6m 16.5m 80.5m 79.6m 84.2m
Goodwill
10.3m 13.7m 31.5m 28m 28m 28m 28m 33.7m 32.3m 32.3m
Long-Term Investments
2.3m 502.7m 442.6m 767.5m 1.1B 1.6B 1.3B 1.9B 1.5B 1.8B
Other Long-Term Assets
375.4m 337.5m 319.9m 379.8m 408.5m 370.1m 442m 518.1m 621.5m 500.8m
Other Assets
10.3m 13.7m 31.5m 28m 28m 28m 28m 33.7m 32.3m 32.3m
Total Assets
2.3B 2.9B 3.4B 3.9B 4.6B 5.2B 6B 7.2B 7.4B 7.9B
Accounts Payable
8.1m 8.4m 23.1m 9.9m 4.1m 3.8m 4.1m 5.6m 6m 7.1m
Accrued Liabilities
96.1m 162.7m 143m 140.3m 182.9m 170.8m 225.8m 292.4m 338.5m 480.9m
Short-Term Debt
0 0 0 0 0 0 0 0 0 0
Current Portion of Long-Term Debt
— — — 250m 0 — — 400m 300m 0
Other Current Liabilities
228.3m 273.6m 110.5m 62.8m 136.3m 130.8m 113.3m 106.4m 93.6m 72.6m
Total Current Liabilities
332.5m 444.7m 276.6m 463m 323.3m 305.4m 343.2m 804.4m 738.1m 560.6m
Long-Term Debt
0 250m 250m 600m 800m 800m 800m 300m 0 0
Other Liabilities
130.9m 63.7m 66.6m 70m 96.5m 104.8m 104.6m 77.8m 181.9m 223.2m
Total Liabilities
463.4m 758.4m 593.2m 1.1B 1.2B 1.2B 1.2B 1.2B 920m 783.8m
Common Stock
700k 700k 700k 700k 700k 700k 700k 700k 800k 800k
Retained Earnings
2.4B 2.8B 3.4B 3.3B 3.8B 4.3B 5B 6B 7.2B 8.6B
Additional Paid In Capital
1.8B 1.9B 1.9B 2B 2.1B 2.2B 2.4B 2.5B 2.7B 2.8B
Unrealized Security Profit/Loss
— (1.9m) (2.3m) 3.7m 10.4m (4.6m) (56.4m) (10.8m) 1.1m 10.8m
Treasury Stock
(2.4B) (2.6B) (2.6B) (2.6B) (2.6B) (2.6B) (2.6B) (2.6B) (3.5B) (4.3B)
Other Equity
(5.9m) 1.5m 13.6m (17.9m) (24.6m) (18.4m) 900k (2m) (4.5m) (9.9m)
Total Equity
1.9B 2.1B 2.8B 2.8B 3.4B 4B 4.8B 6B 6.4B 7.1B
Total Liabilities & Equity
2.3B 2.9B 3.4B 3.9B 4.6B 5.2B 6B 7.2B 7.4B 7.9B
Common Shares Outstanding
43m 43.2m 43.6m 43.9m 44.5m 45.1m 46m 47m 44.8m 43.6m
ALNY
Alnylam Pharmaceuticals Inc

A rapidly scaled RNAi platform moving from R&D losses to product profitability

Intrinsic Value Access required
SOBI
Swedish Orphan Biovitrum AB (publ)

Growing specialty-medicine portfolio with profitable operations and lumpy cash conversion

Intrinsic Value Access required
BIIB
Biogen Inc

A cash-generative biotech transitioning from legacy MS to acquired growth platforms

Intrinsic Value Access required
SMMT
Summit Therapeutics Inc

A pre-commercial oncology developer financed by equity, with operating burn and minimal capital needs

Intrinsic Value Access required

Continue UTH Research

Summary
UTH intrinsic value, competitors valuation, and company profile.
DCF Valuation
UTH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
UTH stock valuation using valuation multiples.
Wall St Estimates
UTH price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financial Statements
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
UTH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financial Statements
Discount Rate
Other United Therapeutics Corp listings:
NASDAQ • USD
UTHR
 F • EUR
UTH
 SWB • EUR
UTH
ALPHA SPREAD
Follow us
Join 362,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.